Possible PBS listing for dabrafenib and trametinib

Possible PBS listing for dabrafenib and trametinib

18 December 2018

Dabrafenib and trametinib are being considered by the Pharmaceutical Benefits Advisory Committee (PBAC) for the adjuvant treatment of resected Stage III melanoma in BRAF positive patients.

Listing on the PBS would provide these treatments at a subsidised price to patients at an earlier stage of disease than currently available.

The Therapeutic Goods Administration (TGA) approved this combination therapy in June 2018 for resected Stage III patients. The combination of dabrafenib and trametinib is listed on the Pharmaceutical Benefits Scheme (PBS) for unresectable Stage III and Stage IV melanoma only.

Should you wish to provide comment to the PBAC, the Consumer Comments portal on the PBS website can be found here. The portal will close on 13 February 2019, prior to the PBAC Meeting in March.

Overcoming resistance to immunotherapy.

Overcoming resistance to immunotherapy. - Copy

New research takes on major challenge to improving survival in melanoma.

Overcoming resistance to immunotherapy.

Overcoming resistance to immunotherapy. - Copy

New research takes on major challenge to improving survival in melanoma.

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.

All Aussies should have access to this lifesaver

All Aussies should have access to this lifesaver

Carrie Palmer writes for The Daily Telegraph about her experience with melanoma. 

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

Julie-Ann Sams knows all too well that melanoma doesn’t discriminate. Life changed for her
youngest son, Toby Rayner, when he was diagnosed with a rare from of iris melanoma that sadly required his left eye to be surgically removed.


 

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

Julie-Ann Sams knows all too well that melanoma doesn’t discriminate. Life changed for her
youngest son, Toby Rayner, when he was diagnosed with a rare from of iris melanoma that sadly required his left eye to be surgically removed.


 

Congratulations to our Conjoint Medical Directors

Congratulations to our Conjoint Medical Directors

Our Conjoint Medical Directors have been announced as Fellows of the Australian Academy of Health and Medical Sciences.

Melanoma diagnosis for Australian Survivor contestant stark warning about the risks of sun exposure

Melanoma diagnosis for Australian Survivor Contestant stark warning about the risks of sun exposure

News reports today of a recently evicted Australian Survivor star being diagnosed with melanoma should serve as a stark warning to all Australians of the serious health risks posed by sun exposure.

60 Minutes' MIA Patient Feature Program

60 Minutes' MIA Patient Feature Program

Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here

The latest research from Dr James Wilmott

The latest research from Dr James Wilmott

Dr James Wilmott is researching how melanoma forms in young people.

Jay Allen MIA's Community Coordinator nominated for NSW Australian of the Year award

Jay Allen MIA's Community Coordinator nominated for NSW Australian of the Year award

Congratulations to MIA’s Community Coordinator and melanoma survivor Jay Allen who has been announced as a nominee for the 2018  Australian of the Year Awards.